This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

Squamous NSCLC

ErbB mutations in patients with squamous NSCLC: a subanalysis of LUX-Lung 8

In a genetic analysis of 245 patients with squamous cell carcinoma (SqCC)of the lung  from the LUX-Lung 8 study, 53 (21.6%) had tumours with at least one ErbB Family mutation.1 Progression-free survival (PFS) and overall survival (OS) were longer with afatinib* versus erlotinib in patients with ErbB wild-type tumours (median PFS: 3.5 vs 2.5 months; hazard ratio[HR]=0.69; 95% confidence interval [CI]: 0.51–0.92; p=0.012; median OS: 8.4 vs 6.6 months; HR=0.81; 95% CI: 0.62–1.05; p=0.115). These effects were more pronounced in afatinib-treated patients with ErbB mutation-positive tumours versus afatinib-treated patients without ErbB mutations (median PFS: 4.9 vs 3.0 months; HR=0.62; 95% CI: 0.37–1.02; p=0.062; median OS: 10.6 vs 8.1 months; HR=0.75; 95% CI: 0.47–1.17; p=0.206). The most marked effect was seen in 12 patients with HER2 mutations.1 The presence of HER2 mutations predicted favourable PFS (interaction p value = 0.006) and OS (interaction p value = 0.003) with afatinib versus erlotinib.1

Did you find this information useful?

References

1

Goss GD, et al. JAMA Oncol 2018 Jun 14. doi: 10.1001/jamaoncol.2018.0775. [Epub ahead of print].

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

Last updated: October 2018